Impacts of the preempt protocol on chronic migraine: an integrative review
DOI:
https://doi.org/10.48208/HeadacheMed.2022.18Keywords:
PREEMPT Protocol, OnabotulinumtoxinA, Chronic migraine, Botulinum Toxin AAbstract
Chronic migraine is an important cause of functional disability and quality of life deficits, affecting 12% of the world population. Therefore, more treatment alternatives that promote better pain control are needed. So, botulinum toxin type A presents itself as a therapeutic option for this purpose. This integrative review aimed to analyze the functionality of the PREEMPT protocol applied for the treatment of chronic migraine, analyzing the time of pain control, the frequency of repetition of the treatment and the possible subtypes of pain that benefit most from botulinum toxin. Data were collected from the National Library of Medicine and Lilacs databases, and the research concluded in July 2022. 31 articles were found, of which only 22 publications were considered eligible to compose this study, and those that contemplated the research objectives were selected. above. Botulinum toxin type A presents an effective, safe and well-tolerated preventive profile for patients with chronic migraine, increasing the patient's quality of life and works in pain control.
Downloads
References
Wiggers A, Ashina H, Hadjikhani N, Sagare A, Zlokovic BV, Lauritzen M and Ashina M. Brain barriers and their potential role in migraine pathophysiology. The Journal of Headache and Pain 2022;23(1):Doi:10.1186/s10194-021-01365-w DOI: https://doi.org/10.1186/s10194-021-01365-w
Steiner T and Saylor D. The Global Burden of Headache. Seminars in Neurology 2018;38(02):182-190 Doi:10.1055/s-0038-1646946 DOI: https://doi.org/10.1055/s-0038-1646946
Goadsby PJ, Lantéri-Minet M, Michel MC, Peres M, Shibata M, Straube A, . . . Hitier S. 21st century headache: mapping new territory. The Journal of Headache and Pain 2021;22(1):Doi:10.1186/s10194-021-01233-7 DOI: https://doi.org/10.1186/s10194-021-01233-7
Burch RC, Buse DC and Lipton RB. Migraine. Neurologic Clinics 2019;37(4):631-649 Doi:10.1016/j.ncl.2019.06.001 DOI: https://doi.org/10.1016/j.ncl.2019.06.001
Mungoven TJ, Henderson LA and Meylakh N. Chronic Migraine Pathophysiology and Treatment: A Review of Current Perspectives. Frontiers in Pain Research 2021;2(Doi:10.3389/fpain.2021.705276 DOI: https://doi.org/10.3389/fpain.2021.705276
Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, . . . Brin MF. OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program. Headache: The Journal of Head and Face Pain 2010;50(6):921-936 Doi:10.1111/j.1526-4610.2010.01678.x DOI: https://doi.org/10.1111/j.1526-4610.2010.01678.x
Ashina M and Ropper AH. Migraine. New England Journal of Medicine 2020;383(19):1866-1876 Doi:10.1056/NEJMra1915327 DOI: https://doi.org/10.1056/NEJMra1915327
Pak AT, ÜStÜN İ and Sengul Y. Botulinum toxin type A wear-off phenomenon in chronic migraine patients: how long does the maximum efficiency last? Arquivos de Neuro-Psiquiatria 2021;79(10):886-890 Doi:10.1590/0004-282x-anp-2020-0542 DOI: https://doi.org/10.1590/0004-282x-anp-2020-0542
Aoki KR. Evidence for Antinociceptive Activity of Botulinum Toxin Type A in Pain Management. Headache: The Journal of Head and Face Pain 2003;43(s1):9-15 Doi:10.1046/j.1526-4610.43.7s.3.x DOI: https://doi.org/10.1046/j.1526-4610.43.7s.3.x
Sposito MMdM. Toxina Botulínica do Tipo A: mecanismo de ação. Acta Fisiátrica 2009;16(1):25-37 Doi:10.11606/issn.2317-0190.v16i1a103037 DOI: https://doi.org/10.11606/issn.2317-0190.v16i1a103037
Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, . . . Turkel CC. OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56-Week PREEMPT Clinical Program. Headache: The Journal of Head and Face Pain 2011;51(9):1358-1373 Doi:10.1111/j.1526-4610.2011.01990.x DOI: https://doi.org/10.1111/j.1526-4610.2011.01990.x
Chiang C-C and Starling AJ. OnabotulinumtoxinA in the treatment of patients with chronic migraine: clinical evidence and experience. Therapeutic Advances in Neurological Disorders 2017;10(12):397-406 Doi:10.1177/1756285617731521 DOI: https://doi.org/10.1177/1756285617731521
Pedraza MI, de la Cruz C, Ruiz M, López-Mesonero L, Martínez E, de Lera M and Guerrero ÁL. OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm. SpringerPlus 2015;4(1):Doi:10.1186/s40064-015-0957-z DOI: https://doi.org/10.1186/s40064-015-0957-z
Grazzi L. Onabotulinumtoxin A for chronic migraine with medication overuse: clinical results of a long-term treatment. Neurological Sciences 2017;38(S1):141-143 Doi:10.1007/s10072-017-2864-2 DOI: https://doi.org/10.1007/s10072-017-2864-2
Grazzi L and Usai S. Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience. Neurological Sciences 2015;36(S1):33-35 Doi:10.1007/s10072-015-2140-2 DOI: https://doi.org/10.1007/s10072-015-2140-2
Torres-Ferrus M, Gallardo VJ, Alpuente A and Pozo-Rosich P. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA. The Journal of Headache and Pain 2020;21(1):Doi:10.1186/s10194-020-01157-8 DOI: https://doi.org/10.1186/s10194-020-01157-8
Álvaro González LC, Fernández García JM, Aranzábal Alustiza I, Castillo Calvo B, Iriondo Etxenagusia I and Rodríguez Antigüedad A. Toxina botulínica tipo A en la migraña crónica refractaria: experiencia en uso compasivo preautorización. Revista de Neurología 2012;55(07):Doi:10.33588/rn.5507.2012210 DOI: https://doi.org/10.33588/rn.5507.2012210
Demiryurek BE, Ertem DH, Tekin A, Ceylan M, Aras YG and Gungen BD. Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine. Neurological Sciences 2016;37(11):1779-1784 Doi:10.1007/s10072-016-2665-z DOI: https://doi.org/10.1007/s10072-016-2665-z
Khalil M, Zafar HW, Quarshie V and Ahmed F. Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK. The Journal of Headache and Pain 2014;15(1):Doi:10.1186/1129-2377-15-54 DOI: https://doi.org/10.1186/1129-2377-15-54
Bendtsen L, Sacco S, Ashina M, Mitsikostas D, Ahmed F, Pozo-Rosich P and Martelletti P. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. The Journal of Headache and Pain 2018;19(1):Doi:10.1186/s10194-018-0921-8 DOI: https://doi.org/10.1186/s10194-018-0921-8
Atraszkiewicz D, Ito R and Bahra A. The efficacy of botulinum toxin type-A for intractable chronic migraine patients with no pain-free time. British Journal of Pain 2021;16(1):41-49 Doi:10.1177/20494637211014544 DOI: https://doi.org/10.1177/20494637211014544
Santoro A, Fontana A, Miscio AM, Zarrelli MM, Copetti M and Leone MA. Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting. Neurological Sciences 2017;38(10):1779-1789 Doi:10.1007/s10072-017-3054-y DOI: https://doi.org/10.1007/s10072-017-3054-y
Vernieri F, Paolucci M, Altamura C, Pasqualetti P, Mastrangelo V, Pierangeli G, . . . Grazzi L. Onabotulinumtoxin‐A in Chronic Migraine: Should Timing and Definition of Non‐Responder Status Be Revised? Suggestions From a Real‐Life Italian Multicenter Experience. Headache: The Journal of Head and Face Pain 2019;59(8):1300-1309 Doi:10.1111/head.13617 DOI: https://doi.org/10.1111/head.13617
Caronna E, Gallardo VJ, Hernández-Beltrán N, Torres-Ferrus M and Pozo-Rosich P. OnabotulinumtoxinA: An Effective Tool in the Therapeutic Arsenal for Chronic Migraine With Medication Overuse. Frontiers in Neurology 2018;9(Doi:10.3389/fneur.2018.00808 DOI: https://doi.org/10.3389/fneur.2018.00808
Aicua-Rapun I, Martínez-Velasco E, Rojo A, Hernando A, Ruiz M, Carreres A, . . . Guerrero AL. Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year. The Journal of Headache and Pain 2016;17(1):Doi:10.1186/s10194-016-0702-1 DOI: https://doi.org/10.1186/s10194-016-0702-1
Lia C, Tosi P, Giardini G, Caligiana L and Bottacchi E. Onabotulinumtoxin A for prophylaxis in chronic migraine: preliminary data from headache regional centre of aosta valley. Neurological Sciences 2014;35(S1):175-176 Doi:10.1007/s10072-014-1764-y DOI: https://doi.org/10.1007/s10072-014-1764-y
Guerzoni S, Pellesi L, Baraldi C and Pini LA. Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment. The Journal of Headache and Pain 2016;17(1):Doi:10.1186/s10194-016-0634-9 DOI: https://doi.org/10.1186/s10194-016-0634-9
Grazzi L and Usai S. Botulinum toxin A: a new option for treatment of chronic migraine with medication overuse. Neurological Sciences 2014;35(S1):37-39 Doi:10.1007/s10072-014-1739-z DOI: https://doi.org/10.1007/s10072-014-1739-z
Lee MJ, Lee C, Choi H and Chung C-S. Factors associated with favorable outcome in botulinum toxin A treatment for chronic migraine: A clinic-based prospective study. Journal of the Neurological Sciences 2016;363(51-54 Doi:10.1016/j.jns.2016.01.054 DOI: https://doi.org/10.1016/j.jns.2016.01.054
Palma Carazo JA, Irimia Sieira P, Fernández Torrón R, Ortega Cubero S, Riverol Fernández M, Luquin Piudo MR and Martínez Vila E. Experiencia clínica del tratamiento con onabotulinumtoxin A en pacientes con migraña refractaria. Revista de Neurología 2012;54(12):Doi:10.33588/rn.5412.2012141 DOI: https://doi.org/10.33588/rn.5412.2012141
Cernuda-Morollón E, Ramón C, Larrosa D, Alvarez R, Riesco N and Pascual J. Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year? Cephalalgia 2014;35(10):864-868 Doi:10.1177/0333102414561873 DOI: https://doi.org/10.1177/0333102414561873
Frampton JE and Silberstein S. OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine. Drugs 2018;78(5):589-600 Doi:10.1007/s40265-018-0894-6 DOI: https://doi.org/10.1007/s40265-018-0894-6
Dodick DW, Silberstein SD, Lipton RB, DeGryse RE, Adams AM and Diener H-C. Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data. Cephalalgia 2019;39(8):945-956 Doi:10.1177/0333102418825382 DOI: https://doi.org/10.1177/0333102418825382
Burstein R, Zhang X, Levy D, Aoki KR and Brin MF. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains. Cephalalgia 2014;34(11):853-869 Doi:10.1177/0333102414527648 DOI: https://doi.org/10.1177/0333102414527648
Pellesi L, Do TP, Ashina H, Ashina M and Burstein R. Dual Therapy With Anti‐CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale? Headache: The Journal of Head and Face Pain 2020;60(6):1056-1065 Doi:10.1111/head.13843 DOI: https://doi.org/10.1111/head.13843
Gazerani P, Staahl C, Drewes AM and Arendt-Nielsen L. The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 2006;122(3):315-325 Doi:10.1016/j.pain.2006.04.014 DOI: https://doi.org/10.1016/j.pain.2006.04.014
Wheeler A and Smith HS. Botulinum toxins: Mechanisms of action, antinociception and clinical applications. Toxicology 2013;306(124-146 Doi:10.1016/j.tox.2013.02.006 DOI: https://doi.org/10.1016/j.tox.2013.02.006
Farinelli I, Coloprisco G, De Filippis S and Martelletti P. Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience. The Journal of Headache and Pain 2006;7(6):407-412 Doi:10.1007/s10194-006-0344-9 DOI: https://doi.org/10.1007/s10194-006-0344-9
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Melissa Helena Rodrigues Silva, Joaquim Fechine de Alencar Neto, Otávio da Cunha Ferreira Neto, Luis Bandeira Alves Neto, Nilson Batista Lemos, Arthur Oliveira Lira, Maria Luísa Rocha, Luís Felipe Ferreira Marques, Victor Egypto Pereira, Victoria Rodrigues Durand, Ana Cristina Veiga Silva, Luiz Severo Bem Junior, Hildo Rocha Cirne de Azevedo Filho
This work is licensed under a Creative Commons Attribution 4.0 International License.
